Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas

NCT04334174 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped accrual not met

Conditions

T Cell Lymphoma

Interventions

DRUG: Brentuximab Vedotin

Sponsor

University of Kansas Medical Center

Collaborators

[object Object]